In Brief
Antiviral treatment is the first line of defense during influenza A pandemics. Holthausen et al. identify a host defense peptide (urumin) from frogs that is virucidal for H1 hemagglutinin (HA)-bearing human influenza A viruses. Urumin targets the conserved stalk region of hemagglutinin and protects naive mice from lethal influenza infection.
INTRODUCTION
Influenza is the most common recurring human respiratory virus (Horimoto and Kawaoka, 2005; Palese, 2004; Webster et al., 1992) . Worldwide there are 3-5 million cases of severe influenza infection annually, which affects 5%-10% of adults and 20%-30% of children and results in 250-500 thousand deaths (Smith et al., 2006; WHO, 2016) . Current vaccination strategies do offer protection; however, pandemic outbreaks occur unexpectedly, limiting our ability to develop vaccines in a timely manner. Additionally, for seasonal influenza A viruses (IAV), mismatches frequently occur between the vaccine and circulating strains (Osterholm et al., 2012) . The emergence of drug-resistant IAV is also a major concern; currently, only neuraminidase (NA) inhibitors are recommended, as adamantane-resistant influenza strains have become widespread (Fiore et al., 2011; Hurt et al., 2006) . Thus, there is a pressing need to develop new antivirals against IAV.
One strategy for creating new influenza antivirals was to take advantage of pre-existing host innate defense mechanisms of other species. Host defense peptides (HDPs) are a critical innate defense mechanism across all species that are far less prone to resistance than conventional drug therapies (Ganz, 2003; Hurt et al., 2006; Zasloff, 2002) . In 1981, Hans Boman showed that the silk moth Hyalophora cecropia survived bacterial infections because of HDPs in their hemolymph (Steiner et al., 1981) . In 1987, Michael Zasloff (Zasloff, 1987) and Dudley Williams (Giovannini et al., 1987) , studying Xenopus laevis, elegantly demonstrated that amphibians secrete large quantities of unique peptides to defend against microbial infection (Bevins and Zasloff, 1990; Seo et al., 2012; Wang et al., 2009; Zasloff, 2002) . These peptides have evolved to protect the frogs against pathogens that they might encounter, but other studies have shown that amphibian HDPs also are active against human viruses like HSV-1, HSV-2, and HIV-1 in vitro (Albiol Matanic and Castilla, 2004; Belaid et al., 2002; Chinchar et al., 2004; Lorin et al., 2005; Mulder et al., 2013; Yasin et al., 2000) . HDPs have also been shown to have anti-cancer (Conlon et al., 2014; Mulder et al., 2013) and anti-diabetic (Conlon et al., 2014) activity. Therefore, HDPs may represent an untapped resource for novel drug discovery.
As amphibian HDPs have shown activity against other human viruses, we sought to determine whether they also contained HDPs against human IAV. We identified HDPs from skin secretions of frogs and identified a peptide that was virucidal against H1 hemagglutinin (HA)-bearing human IAV. This peptide targeted the conserved stalk region of H1 HA, physically destroyed influenza virions, and protected naive mice from lethal influenza infection. Urumin specifically targets the stalk region of hemagglutinin, like the way that antibodies induced by universal influenza vaccines target the virus, and may prove a useful antiviral therapy, especially given that it is effective against drug-resistant H1 influenza strains.
RESULTS
A Peptide from Hydrophylax bahuvistara Exhibits Anti-A/ PR/8/1934 Influenza Virus Activity In Vitro Cohorts of the Indian frog Hydrophylax bahuvistara, a species currently being studied for antimicrobial peptides (Vineeth Kumar et al., 2016) , were captured and skin secretions were collected after mild electrical stimulation. Animals were subsequently returned to their natural habitat, unharmed. We identified 32 HDPs from the secretions by molecular cloning of HDP cDNAs and synthesized the peptides for screening. We screened these peptides for potential activity against the human H1N1 influenza A virus A/Puerto Rico/8/1934 (PR8) using a plaque assay. We incubated individual peptides or control ovalbumin (OVA) peptide with the virus for 2 hr, plated them with Madin-Darby Canine Kidney epithelium (MDCK) cells, and counted virus plaques 3 days later. We identified four peptides that showed greater than 50% reduction of viral titers as compared to the control OVA peptide ( Figures 1A and S1 ). As HDPs are often toxic to mammalian cells, especially at higher concentrations, we measured the toxicity of these peptides by incubating them with human red blood cells (RBCs) for 1 hr and assessed hemolysis. Of the four peptides, #25 showed no toxicity up to 320 mM in PBS ( Figure 1B ). This peptide reached a 20% level of toxicity only at 1,430 mM ( Figure 1C ). We named this peptide urumin from the word ''urumi,'' a deadly whip sword that originated from the same geographical region as H. bahuvistara. Urumin is a 27-amino acid peptide with a net 2+ positive charge and no known homology to any other HDP ( Figure 1D ). Of the four peptides with antiviral activity, urumin was chosen for further characterization due to its low toxicity.
Next, we assessed the dose response and the kinetics of urumin's antiviral activity. The IC 50 of urumin was 3.8 mM ( Figure 1E ) and increasing the peptide concentration led to significantly increased inhibition of viral growth (p = 0.0004; Figure S2) . The therapeutic index (TI) of a host defense agent compares the therapeutic effect to the toxicity and is often used as a measure of the safety of a therapeutic agent. The higher the TI is over 1, the more favorable the safety of the therapeutic. For urumin, the toxic dose (TD 50 ) was 2,450 mM ( Figure 1C ) and IC 50 was 3.8 mM ( Figure 1E ). TD 50 /IC 50 produces a TI of 644.7, indicative of a favorable therapeutic profile. Additionally, the antiviral activity occurred within 15 min of incubation with the peptide (p < 0.0001; Figure 1F ). The antiviral effect of urumin was specific to IAV as urumin had no antiviral effect on any of the other viruses tested, which included HIV, SIV, HSV-II, hepatitis C, Ebola, Zika, and Dengue viruses (not shown).
Urumin Is Specific for H1 Hemagglutinin and Targets the Conserved Stalk Region of H1 HA As urumin showed specificity for PR8 influenza virus, we sought to determine whether this antiviral effect was strain or subtype specific. We tested urumin against eight different H1N1 and four different H3N2 IAVs. These viruses were circulating strains from 1934 to 2013 and included the 2009 pandemic strain (A/California/04/2009) and a 2013 drift variant of this virus (A/Tennessee/F5001/2013). Of the 12 viruses, urumin inhibited all 8 H1N1 viruses by at least 60%, with titers of some strains decreasing by more than 90%. In contrast, all 4 of the H3N2 viruses were reduced by less than 50%, with 3 of 4 being reduced by less than 30% (Figure 2A ). Overall, urumin had a significantly greater effect against H1N1 strains than H3N2 influenza strains (p < 0.0001; Figure 2B ). These results suggested that urumin could be targeting H1 HA, N1 NA, or both. To more precisely determine the specificity of urumin, we used reassortant PR8 viruses that bear the same six internal gene segments but differ in their HA and NA expression. We tested four PR8 reassortant viruses-H1N1, H1N2, H3N1, and H3N2-against urumin or the OVA control. Of these viruses, urumin significantly inhibited H1N1 and H1N2 viruses, while the H3N1 and H3N2 were unaffected, demonstrating that urumin inhibited IAVs that bear H1 HA but not H3 HA or N1/N2 NA (p < 0.0001; Figure 2C ).
The HA protein is a trimer that consists of a conserved stalk region and a variable globular head region (Copeland et al., 1986) . Targeting the conserved stalk region of HA, as in broadly neutralizing antibodies (Ekiert and Wilson, 2012; Krammer and Palese, 2013) or computationally designed stalk binding proteins (Koday et al., 2016) , present a promising approach to neutralizing human IAVs. As urumin targeted H1 HA and inhibited 8 H1N1 viruses that circulated over a span of 75 years, we reasoned that it probably targeted the conserved stalk and not the variable globular head region. To test this, we utilized the H9N3 virus, A/guinea fowl/Hong Kong/WF10/1999, and a chimeric form of this virus, wherein the HA consists of the H9 head region and the PR8 H1 stalk . As expected, urumin inhibited the chimeric virus with the H1 stalk and H9 head and produced a similar level of reduction observed with PR8. In contrast, the non-chimeric wild-type H9N3 virus (H9 stalk and H9 head) was not inhibited ( Figure 2D ), suggesting that urumin specifically targeted the stalk region of H1 HA. To confirm this, we tested whether urumin would block the binding of monoclonal antibodies (mAbs) directed to the stalk but not head region of HA. We conducted a competitive ELISA wherein recombinant purified HA was incubated with serially diluted urumin or OVA and assessed the ability to block the binding of mAbs directed at the head or stalk regions of HA (Wrammert et al., 2011) . Urumin inhibited the binding of the anti-stalk but not anti-head mAbs ( Figures 2E-2G ). These data demonstrated that urumin binds to the conserved stalk region of H1 HA to inhibit IAV.
Urumin Is Effective against Drug-Resistant Influenza Viruses
Current anti-influenza drugs target NA and M2 proteins (Fiore et al., 2011; Hurt et al., 2006) . As urumin targets HA and not NA or M2, we sought to determine whether urumin is effective at neutralizing drug-resistant H1N1 viruses. We tested urumin against seven drug-resistant influenza strains. These viruses included isolates resistant to oseltamivir carboxylate (A/Louisiana/08/2013 H275Y, A/Texas/23/2012 H275Y), zanamivir and peramivir (A/District of Columbia/02/2014 Cl1-7), or oseltamivir carboxylate and zanamivir (A/Chile/1579/2009 I223K). Viruses generated by reverse genetics were also tested, including a control drug-sensitive pandemic H1N1 rgCal/04/09 wild-type, oseltamivir-resistant mutants rgCal/04/09 H275Y and rgCal/04/09 H275Y S247N, an oseltamivir-sensitive A/New York/08-1253/ 2008 (rg1253 (S)), and oseltamivir-resistant A/New York/ 08-1326/2008 (rg1326(R)) Seibert et al., 2012) . Our data showed that urumin significantly reduced the viral titers of all drug-resistant and drug-sensitive H1N1 virus strains assessed ( Figure 2H ) and if drug-resistant H1 HA A) 32 peptides isolated from the skin of H. bahuvistara were incubated with H1N1 PR8 influenza for 2 hr and virus growth was assessed by plaque assay. OVA control-treated virus was set as 100% virus growth. Peptides were used at 10 mM, except peptides 11, 26, 28, 29, 32, which were tested at lower concentrations due to hemolytic activity at 10 mM. Peptides highlighted in red significantly reduced viral titers in comparison to OVA control. (B and C) Serially diluted frog peptides or OVA in PBS were incubated with human RBCs for 1 hr. Peptide toxicity was compared to lysis induced by 0.1% Triton X-100, which was set as 100% cell lysis, and PBS as 0% lysis. (D) Sequence of urumin on the Hopp & Woods amino acid hydrophilicity scale (Hopp and Woods, 1981) . (E) Graded concentrations of urumin (0.6-320 mM) were incubated with PR8 for 2 hr and IC 50 was determined by peptide-induced virus growth inhibition as assessed by plaque assay. (F) 10 mM urumin or OVA was incubated with PR8 for 5-60 min and kinetics of urumin activity was determined by virus growth inhibition as assessed by plaque assay. Pooled results from three independent experiments shown in (A)-(C), (E), and (F). Statistical significance *p < 0.05, **p < 0.005, ***p < 0.0005 was determined by one-way ANOVA (p < 0.0001) with Bonferonni post-tests against OVA control (A) and two-way ANOVA (peptide p < 0.0001) with Bonferonni post-tests (F). Error bars denote means ± SEM. Please also see Figures S1 and S2. influenza strains become prevalent, urumin could be used against these isolates.
Urumin Disrupts Influenza Virus Integrity
Since we showed that urumin effectively inhibited growth of H1 HA-bearing IAV, we next determined how the peptide functioned. It was possible that urumin was actively destroying influenza virions or that it was blocking viral growth. To test this, we incubated PR8 virus with urumin or OVA for 2 hr and then imaged virus by electron microscopy. Our data showed that OVA-treated virions were intact ( Figure 3A) , while urumin-treated influenza virions were destroyed ( Figure 3B ). These data indicate that urumin is actively destroying influenza virions.
Urumin Requires Sequence Fidelity and Chirality for Activity To determine which amino acid residues in urumin were most critical for anti-influenza activity, we generated 23 alanine scan mutant urumin peptides ( Figure S3A ; Lefè vre et al., 1997) . First, we assessed whether these mutations increased toxicity to human RBCs. None of the alanine mutants showed toxicity to (C) 100 mM urumin or OVA peptide was incubated with four reassortant PR8 viruses that shared all six internal gene segments and differed only in HA and NA segments for 2 hr and peptide-induced virus growth inhibition was assessed by plaque assay. (D) 100 mM urumin or OVA was incubated with PR8, H9N3 A/guinea fowl/Hong Kong/WF10/99, and a chimeric H9N3 including the WF10 head region and the PR8 conserved stalk for 2 hr and peptide-induced virus growth inhibition was assessed by plaque assay. (E-G) We incubated plate-bound purified HA with serially diluted urumin or OVA peptide (3 to 0.02 mg) followed by anti-HA head-specific mAbs EM4C04 (E), or stalk-specific mAbs, SF093805 (F), and SF701F02 (G). Binding of mAbs was determined by ELISA, OVA control was set as 100% binding. This competitive ELISA shows that urumin peptide inhibits binding of anti-stalk but not anti-stem mAbs. RBCs, except for a mutation at the third residue, where we observed 20% lysis at the high concentration of 160 mM (Figure S3B) . To test the mutants for anti-influenza activity, we utilized a focus-forming assay (FFA) against PR8, which allowed us to move from 6-to 12-well plates to a 96-well format. We infected MDCK-SIAT1 cells, which overexpress a2,6-linked sialic acid (Oh et al., 2008) and increase experimental sensitivity. Of the 23 mutants, 13 (57%) showed less antiviral activity than urumin, 10 (43%) had equivalent activity to urumin, and no mutations significantly improved peptide-induced viral reduction ( Figure 3C ).
We also tested whether peptide chirality had an impact on the effectiveness of urumin anti-influenza activity. To conduct this experiment, a stereoisomer variant of urumin was produced using D rather than L amino acids. This D amino acid urumin variant, like the L variant, elicited no toxicity to human RBCs (Figure S3C) . We then assessed anti-PR8 activity of D-urumin in comparison to L-urumin as well as OVA control. In contrast to L-urumin, D-urumin showed no reduction of PR8 virus, demonstrating that urumin recognizes a target with a chiral center (Figure 3D) . Thus the specificity of urumin is exquisite, requiring sequence fidelity and chirality.
Intranasal Administration of Urumin Reduces InfluenzaInduced Morbidity, Mortality, and Lung Viral Titers In Vivo Next, we determined whether urumin could exert its antiviral activity in vivo by testing the extent to which peptide treatment could protect naive mice infected with live mouse-adapted PR8 virus. Cohorts of BALB/c mice were treated with 20 mg urumin or an OVA control, administered intranasally (i.n.). Five minutes later, they were infected with 2 3 LD 50 of live mouseadapted PR8 influenza i.n. The mice were then treated daily for the next 3 days with 20 mg of urumin or OVA i.n. (Ideally, the peptide should be delivered systemically, but because that strategy still needs to be resolved, we chose the suboptimal i.n. route for this proof of principle confirmation that urumin is functional in vivo.) We assessed morbidity (percent mass reduction) and mortality (survival) over 14 days after infection. Urumintreated mice had significantly less morbidity than control mice (p < 0.0001; Figures 4A and 4B) . Furthermore, 70% of urumintreated mice survived 2 3 LD 50 influenza infection while only 20% of OVA-treated control mice survived ( Figure 4C ).
We also determined the extent to which i.n. administration of urumin reduced lung virus titers in infected mice. Cohorts of BALB/c mice were administered with 6.6 mg, 20 mg, or 60 mg of urumin or OVA and infected with 2 3 LD 50 of live mouse-adapted PR8 in the same manner as the morbidity and mortality analysis described above. The animals were euthanized at either day 3 or 6, and lung viral titers were assessed by FFA. We found that there is a significant decrease in viral focus-forming units per gram of lung tissue in the urumin-treated cohort as compared to control mice at day 6 (80% with 6.6 mg p < 0.01, 82% with 20 mg p < 0.01, and 92% with 60 mg p < 0.05; Figure 4D ). Taken together, the data demonstrate that urumin is effective at reducing influenza-induced morbidity, mortality, and lung viral titers in vivo.
DISCUSSION
We demonstrated that an amphibian innate defense peptide can be harnessed for combating human IAVs. The peptide, urumin, is specific for H1 HA and targeted the conserved stalk region much like broadly neutralizing stalk-specific antibodies (Krammer et al., 2015; Pica and Palese, 2013) . The specificity of this peptide is exquisite in that, in contrast to the L-form of urumin, the D-enantiomer peptide, which has the same amino acid sequence but mirror image conformation with respect to the L-peptide, failed to inhibit virus. While most HDPs act by destabilizing membranes, peptides with specificity for cell surface molecules, though rare, have also been described. Nisin is a 14-amino acid amphipathic peptide produced by Lactococci bacteria. Nisin binds with high affinity to Lipid II, the fatty acyl proteoglycan anchor in the bacterial membrane. After binding, Nisin diffuses into the surrounding membrane and causes killing (Brö tz et al., 1998) . Similarly, urumin specifically targeted a cell surface protein, but the mechanism by which it lyses virus still needs to be elucidated.
There is a pressing need to develop new antiviral agents against IAVs, particularly those that can be used during pandemic outbreaks where there is insufficient time to produce vaccines, or when the predominant seasonal strains do not match those selected for the annual vaccines (Luke and Subbarao, 2006) . Current antivirals target the M2 or NA proteins, and a single mutation is often sufficient to render the viruses drug-resistant (Fiore et al., 2011; Hurt et al., 2006) . Because of these concerns, antiviral peptides against influenza provide a strategy for combating these viruses (Skalickova et al., 2015) . Antiviral peptides against influenza are often separated into three target categories: peptides that inhibit viral replication by interfering with the viral polymerase like an inhibitory peptide designed to bind and block protein-protein interaction (Ghanem et al., 2007) , peptides that use electrostatic interactions to disrupt the membrane like the human cathelicidin LL-37 (Tripathi et al., 2013) , and peptides that interact with HA to block viral fusion and entry like a peptide derived from the signal sequence of fibroblast growth factor 4 (Jones et al., 2006) . The mechanism of urumin does not fit into any of these categories. By specifically binding to HA and causing viral disruption, we believe that urumin represents a unique class of antiviral agent. By binding the conserved stalk region of H1 HA, we speculate that a combination of conformational changes in HA and electrostatic forces upon the membrane could presumably lead to viral destruction. Future studies will determine the specific binding site and mechanism of urumin's virucidal activity. Additionally, strategies to systemically deliver urumin in vivo will be undertaken. 
EXPERIMENTAL PROCEDURES Skin Secretion Harvesting
Harvesting skin secretions was performed as previously described (Vineeth Kumar et al., 2017) . Adult H. bavuvistara frogs (both sexes, n = 15) were collected from Kerala, India, under license from the Kerala Forest Department. Skin secretions were collected by mild transdermal electrical stimulation and fixed in liquid nitrogen. Frogs were released back into habitat in a healthy state.
Molecular Cloning of cDNAs Encoding HDPs
Molecular cloning was performed as previously described (Vineeth Kumar et al., 2017) . RNA was isolated from secretions using Dyna beads (Dynal Biotech) and a cDNA library was constructed using SMARTerTMcDNA Amplification Kit (Clontech). Advantage DNA Polymerase (Clontech) was used for PCR and gel-purified PCR products were cloned into pGEM-T easy vector system (Promega) and sequenced.
Peptides 32 peptide sequences were identified from H. bahuvistara. Peptides were synthesized at Genscript, Genemed Biotechnologies, and Dr. Brian Evavold's laboratory at Emory University. All peptides were synthesized at purity greater than 80% without specific disulfide bridge modifications. For a control, OVA 257-264 (InvivoGen) was used. 
Influenza Viruses

Plaque Assay
Assay was performed as previously described (Kim et al., 2009 ). IAVs (50-100 pfu) were treated with peptides for 2 hr at 37 C and the extent of viral inhibition was measured by plaque assay.
Hemolysis Peptide Toxicity Assay
Serially diluted peptides in PBS were incubated with single donor human RBCs (Innovative Research) for 1 hr at 37 C. PBS was used as a 0% lysis control and 0.1% Triton X-100 as 100% lysis. Plates were centrifuged at 300 3 g, 4 C for 5 min to pellet non-lysed RBCs. Supernatants were removed and hemoglobin release was detected by absorbance at 450 nm.
Influenza Focus-Forming Assay
Peptides were incubated with IAV (80-100 FFU/well) in Opti-MEM at 37 C for 2 hr. Peptide-treated virus was used to infect MDCK-SIAT1 cells and incubated at 37 C for 1.5 hr, overlaid with methylcellulose, and incubated overnight at 37 C. Cells were fixed with ice-cold methanol/acetone (1:1)
for 30 min and spots developed using anti-Influenza NP-antibody (Millipore MAB8257B). Electron Microscopy 40 mM urumin or OVA was incubated with 100 pfu PR8 for 2 hr in serum-free DMEM with 1% antibiotics and then processed for transmission electron microscopy at the Robert P. Apkarian Integrated Electron Microscopy Core at Emory University.
Mice BALB/c mice, purchased from The Jackson Laboratory, were maintained specific-pathogen-free in accordance with the institutional guidelines of Emory University's Animal Care and Use Committee. All control and experimental mice were age-and sex-matched.
Peptide Administration and Live Virus Challenge
Cohorts of BALB/c mice were anesthetized and administered 20 mg urumin or OVA in 20 mL i.n., and then 5 min later infected with 2 3 LD 50 of mouse-adapted PR8 in PBS (30 mL volume, i.n.). On each of the following 3 days, mice were anesthetized and given 20 mg of urumin or OVA in 20 mL, i.n. For lung viral titer assessment, cohorts of mice were administered with 60 mg, 20 mg, or 6.6 mg doses of urumin or OVA (20 mL volume, i.n.) and infected with 2 3 LD 50 mouse adapted PR8 influenza 5 min later. On each of the following 3 days, mice were given doses of urumin or OVA i.n.
Morbidity and Mortality Assessment
Cohorts of BALB/c mice (n = 10 per group) that were administered peptide and infected with live influenza, as described above, were weighed daily starting on day 0 through 14. Morbidity was assessed by percent weight loss, in comparison to each individual mouse's mass prior to infection. If the mass of a mouse dropped below 80% of initial body weight, it was euthanized as per IACUC guidelines and counted toward virus-induced mortality.
Lung Viral Titer Assessment
On day 3 or 6 after infection, after being administered peptide and virus, BALB/c mice (n = 5 per group) were euthanized and their lung tissue removed and weighed. The lung tissue of each mouse was homogenized and cleared by centrifugation for 10 min at 600 3 g and 4 C. The supernatant was taken and the viral titers were assessed using the influenza virus FFA described above.
Statistical Analysis
Statistical significance was verified by the Student's t test, ANOVA, and Kaplan-Meier survival analysis (Log-rank (Mantel-Cox) test). 
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